Amneal Pharmaceuticals, Inc. (AMRX)
20.38
-0.10
(-0.49%)
USD |
NASDAQ |
Oct 23, 16:00
20.37
-0.01
(-0.05%)
Pre-Market: 20:00
Amneal Pharmaceuticals Enterprise Value : 9.247B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 9.247B |
| October 22, 2026 | 9.279B |
| October 21, 2026 | 9.190B |
| October 20, 2026 | 9.075B |
| October 19, 2026 | 8.922B |
| October 16, 2026 | 8.864B |
| October 15, 2026 | 8.887B |
| October 14, 2026 | 8.775B |
| October 13, 2026 | 8.989B |
| October 12, 2026 | 9.136B |
| October 09, 2026 | 9.097B |
| October 08, 2026 | 9.014B |
| October 07, 2026 | 9.014B |
| October 06, 2026 | 9.220B |
| October 05, 2026 | 9.238B |
| October 02, 2026 | 9.222B |
| October 01, 2026 | 9.148B |
| September 30, 2026 | 9.171B |
| September 29, 2026 | 9.190B |
| September 28, 2026 | 9.286B |
| September 25, 2026 | 9.053B |
| September 24, 2026 | 9.064B |
| September 23, 2026 | 8.912B |
| September 22, 2026 | 8.966B |
| September 21, 2026 | 9.177B |
| Date | Value |
|---|---|
| September 18, 2026 | 8.714B |
| September 17, 2026 | 8.577B |
| September 16, 2026 | 8.513B |
| September 15, 2026 | 8.056B |
| September 14, 2026 | 8.238B |
| September 11, 2026 | 8.171B |
| September 10, 2026 | 8.127B |
| September 09, 2026 | 8.248B |
| September 08, 2026 | 8.184B |
| September 04, 2026 | 8.309B |
| September 03, 2026 | 8.446B |
| September 02, 2026 | 8.507B |
| September 01, 2026 | 8.385B |
| August 31, 2026 | 8.318B |
| August 28, 2026 | 8.340B |
| August 27, 2026 | 8.491B |
| August 26, 2026 | 8.484B |
| August 25, 2026 | 8.462B |
| August 24, 2026 | 8.417B |
| August 21, 2026 | 8.459B |
| August 20, 2026 | 8.455B |
| August 19, 2026 | 8.523B |
| August 18, 2026 | 8.548B |
| August 17, 2026 | 8.621B |
| August 14, 2026 | 8.535B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Liquidia Corp. | 3.699B |
| Eli Lilly & Co. | 1.245T |
| Johnson & Johnson | 662.44B |
| Merck & Co., Inc. | 405.39B |
| Viatris, Inc. | 33.01B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 69.61M |
| Revenue (Quarterly) | 796.20M |
| Total Expenses (Quarterly) | 738.54M |
| EPS Diluted (Quarterly) | 0.1757 |
| Gross Profit Margin (Quarterly) | 42.01% |
| Profit Margin (Quarterly) | 8.74% |
| Earnings Yield | 2.35% |
| Operating Earnings Yield | 7.15% |
| Normalized Earnings Yield | 3.049 |